Cullinan Therapeutics (CGEM) Institutional Ownership
13F filers reported holding 0.3% of Cullinan Therapeutics (CGEM) shares as of Sep 30, 2026, across 21 filers.
- Held by 13F filers
- 0.3%
- Sep 30, 2026
- 13F filers
- 21
- quarter ended Sep 30, 2026
- 13F value
- $2.8M
- 179,153 shares
- Quarter's fund flow
- Mild accumulation
- 3 new · 3 closed
Is the smart money (institutions and insiders) accumulating or distributing? One lagging input, not a buy signal.
| Date | Name | Role | Type | Shares | Price** | SEC filing |
|---|---|---|---|---|---|---|
| Sep 8, 2026 | Michaelson Jennifer | Chief Scientific Officer | Acquired · Option exercise | 4,000 | $4.30 | ↗ |
| Sep 8, 2026 | Michaelson Jennifer | Chief Scientific Officer | Disposed · Open-market sale | 8,000 | $21.57 | ↗ |
| Sep 8, 2026 | Michaelson Jennifer | Chief Scientific Officer | Disposed · Option exercise | 4,000Stock Option (Right to Buy) | — | ↗ |
| Aug 13, 2026 | Michaelson Jennifer | Chief Scientific Officer | Acquired · Option exercise | 30,000 | $4.30 | ↗ |
| Aug 13, 2026 | Michaelson Jennifer | Chief Scientific Officer | Disposed · Open-market sale | 30,000 | $20.26 | ↗ |
| Aug 13, 2026 | Michaelson Jennifer | Chief Scientific Officer | Disposed · Option exercise | 30,000Stock Option (Right to Buy) | — | ↗ |
| Jul 6, 2026 | Michaelson Jennifer | Chief Scientific Officer | Acquired · Option exercise | 4,000 | $4.30 | ↗ |
| Jul 6, 2026 | Michaelson Jennifer | Chief Scientific Officer | Disposed · Open-market sale | 8,000 | $17.82 | ↗ |
| Jul 6, 2026 | Michaelson Jennifer | Chief Scientific Officer | Disposed · Option exercise | 4,000Stock Option (Right to Buy) | — | ↗ |
| Jun 30, 2026 | SUMER JACQUELYN L | Chief Legal Officer | Acquired · Grant / award | 2,470 | $8.60 | ↗ |
| Jun 30, 2026 | Fenton Mary Kay | Chief Financial Officer | Acquired · Grant / award | 1,541 | $8.60 | ↗ |
| Jun 16, 2026 | Rosenberg Anthony | director | Acquired · Grant / award | 25,319Stock Option (Right to Buy) | — | ↗ |
| Jun 16, 2026 | Meek David D. | director | Acquired · Grant / award | 25,319Stock Option (Right to Buy) | — | ↗ |
| Jun 16, 2026 | Webster Stephen W | director | Acquired · Grant / award | 25,319Stock Option (Right to Buy) | — | ↗ |
| Jun 16, 2026 | Allen Andrew R | director | Acquired · Grant / award | 21,781Stock Option (Right to Buy) | — | ↗ |
| Jun 16, 2026 | Thistle Mary | director | Acquired · Grant / award | 25,319Stock Option (Right to Buy) | — | ↗ |
| Jun 16, 2026 | Doyle Mittie | director | Acquired · Grant / award | 21,781Stock Option (Right to Buy) | — | ↗ |
| May 5, 2026 | Michaelson Jennifer | Chief Scientific Officer | Acquired · Option exercise | 4,000 | $4.30 | ↗ |
| May 5, 2026 | Michaelson Jennifer | Chief Scientific Officer | Disposed · Open-market sale | 7,800 | $14.60 | ↗ |
| May 5, 2026 | Michaelson Jennifer | Chief Scientific Officer | Disposed · Open-market sale | 200 | $15.58 | ↗ |
* Holdings as reported for Sep 30, 2026, 49 days old; funds file up to 45 days after each quarter-end, so the newest complete quarter runs 45 to 135 days behind.
** A price of “—” marks an option exercise, RSU vest or a filing without a usable per-share price, not a $0 trade.
Common questions
How much of Cullinan Therapeutics do institutions hold?
13F filers reported holding 0.3% of Cullinan Therapeutics' shares as of Sep 30, 2026, across 21 filers.
How many 13F filers hold Cullinan Therapeutics?
Cullinan Therapeutics was held by 21 13F filers as of Sep 30, 2026.
Not investment advice.

